Bronchiectasis non associated to Cystic Fibrosis (BQ-noFQ), Cystic Fibrosis (CF) and immune deficiencies
Objectives
- To study the epidemiological, clinical and microbiological characteristics of BQ-noFQ
- Study the effect of inflammatory response (local and systemic) in the course of the disease
- Study the effectiveness of nonpharmacological treatment and its implication on the quality of life related to health
Ongoing projects
- To investigate the epidemiology and the clinical-microbiological of BQ-noFQ
- To analyze and compare the effectiveness of airway clearance techniques with different degrees of autonomy in patients with BQ-noFQ
- To evaluate short-term effect of inhaled hyperosmolar agents in patients with BQ-noFQ: tolerability and modification of the rheological properties of secretions
- To study the prognostic value of new biomarkers in exacerbations of BQ-no CF
Achievements
- Recruitment of a respiratory physiotherapist to carry on research protocols in this line of research
- Creating a database of patients with BQ-noFQ
- Fundraising from public and / or private funding
Future challenges
- To evaluate and analyze the clinical impact generated by the innate and adaptive immune response to chronic infection
- To evaluate the impact and long-term effects generated by respiratory therapy (FR) in the progression of the disease in subjects with BQ-noFQ
- To study the cost-effectiveness of long-term pulmonary rehabilitation program in patients with BQ-noFQ
Publications
Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
Fernández-Barat L, Ciofu O, Kragh KN, Pressler T, Johansen U, Motos A, Torres A, Hoiby N.
J Cyst Fibros. 2017 Mar;16(2):222-229. doi: 10.1016/j.jcf.2016.08.005. Epub 2016 Sep 17.
Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations.
Menéndez R, Méndez R, Polverino E, Rosales-Mayor E, Amara-Elori I, Reyes S, Sahuquillo-Arce JM, Fernández-Barat L, Alcaraz V, Torres A.
BMC Infect Dis. 2017 Sep 30;17(1):659. doi: 10.1186/s12879-017-2754-5.
Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study.
Menéndez R, Méndez R, Polverino E, Rosales-Mayor E, Amara-Elori I, Reyes S, Posadas T, Fernández-Barat L, Torres A.
Respir Res. 2017 Sep 30;18(1):176. doi: 10.1186/s12931-017-0659-x.
European Respiratory Society guidelines for the management of adult bronchiectasis.
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD.
Eur Respir J. 2017 Sep 9;50(3).
Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.
Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T; EMBARC/BRR definitions working group.
Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. doi: 10.1183/13993003.00051-2017. Print 2017 Jun.
People working in this line
Lines list
- Animal Model
- Bronchiectasis non associated to Cystic Fibrosis (BQ-noFQ), Cystic Fibrosis (CF) and immune deficiencies
- Community-Acquired Pneumonia (CAP)
- Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
- Networks, European Projects and Collaborations
- Noninvasive Ventilation (NIV)
- Pulmonary complications in immunocompromised (IC) patients
- Translational research laboratory for advanced microbiology diagnosis and pathogen-host response in respiratory infections
- Ventilator-Associated Pneumonia (VAP)
